Amgen

Amgen Inc. is a biotechnology company headquartered in Thousand Oaks, California. Amgen discovers, develops, and delivers human therapeutics, with a portfolio spanning oncology, inflammation, nephrology, and bone health. Product labels, SEC filings, and trial registries provide the evidentiary base for this reference profile.

Amgen's oncology portfolio includes bispecific T-cell engagers and supportive care agents listed in FDA databases. In inflammation, Enbrel and Otezla appear in approved product records. Bone health includes Prolia and Evenity. The Horizon Therapeutics acquisition, completed in 2023, added rare disease medicines such as Tepezza and Krystexxa per SEC transaction disclosures.

• SEC filings document the Horizon acquisition and associated integration planning.
• FDA databases list Amgen biosimilar and originator products across multiple categories.
• ClinicalTrials.gov shows active studies in hematologic malignancies and immunology.
• Investor reports describe capital return and pipeline investment priorities.

Amgen's pipeline is summarized annually in 10-K filings with references to phase and therapeutic area. Business development includes partnerships and acquisitions disclosed to the SEC. For asset-level status, use FDA actions and ClinicalTrials.gov as primary sources.